Patents by Inventor Roshantha A. Chandraratna

Roshantha A. Chandraratna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of cancer with specific RXR agonists
    Patent number: 10973788
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: April 13, 2021
    Assignee: Io Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • RAR SELECTIVE AGONISTS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20210100844
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
    Type: Application
    Filed: December 16, 2020
    Publication date: April 8, 2021
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF MUSCULAR DISORDERS WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES
    Publication number: 20210077445
    Abstract: The present specification provides methods of treating a muscular disorder with a combination of a RXR agonist and a thyroid hormone.
    Type: Application
    Filed: October 7, 2020
    Publication date: March 18, 2021
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Autoimmune disorder treatment using RXR agonists
    Patent number: 10945976
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: March 16, 2021
    Assignees: Io Therapeutics, Inc., Trustees of Dartmouth College
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
    Patent number: 10946001
    Abstract: The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 16, 2021
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
    Patent number: 10940127
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: March 9, 2021
    Assignees: Io Therapeutics, Inc., The Johns Hopkins University
    Inventors: Gabriel Ghiaur, Richard J. Jones, Alonso Salvador, Roshantha A. Chandraratna
  • Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids
    Patent number: 10919835
    Abstract: Provided herein are compounds useful for the preparation of compounds that have retinoid-like biological activity. Also provided herein are processes for the preparation of compounds that have retinoid-like biological activity.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: February 16, 2021
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Vidyasagar Pradeep Vuligonda, Thomas Jacks, Peter Wade, Andrew Thompson
  • Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 10881628
    Abstract: Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: January 5, 2021
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 10874628
    Abstract: Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: December 29, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • RAR selective agonists in combination with immune modulators for cancer immunotherapy
    Patent number: 10874694
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: December 29, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 10874627
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: December 29, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 10857117
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: December 8, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 10842764
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: November 24, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
    Patent number: 10835507
    Abstract: The present specification provides methods of treating a muscular disorder with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: November 17, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES
    Publication number: 20200345675
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Application
    Filed: July 21, 2020
    Publication date: November 5, 2020
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES
    Publication number: 20200330418
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Application
    Filed: July 2, 2020
    Publication date: October 22, 2020
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 10806713
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: October 20, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 10702489
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: July 7, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Autoimmune disorder treatment using RXR agonists
    Patent number: 10695307
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: June 30, 2020
    Assignees: Io Therapeutics, Inc., Trustees of Dartmouth College
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 10695312
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: June 30, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders